Company Overview and News
NEW YORK, Oct 16 — Bank of America Corp's loan growth lagged rivals and fees from advising on deals and underwriting bonds fell in the third quarter, sending its share price 1.7 lower even as profit beat expectations.
WFCNP WFC C CGBBW
7h investorplace - 1
The market fought back on Friday, with the S&P 500 gaining 1.42% on the last trading day of the week. Advanced Micro Devices (NASDAQ:AMD) and Microsoft (NASDAQ:MSFT) led the charge, up 4.1% and 3.5%, respectively. Traders were flocking back into their favorite tech names, many of which were hit exceedingly hard on Wednesday and Thursday. But that wasn’t anywhere near enough strength to undo the damage done earlier in the week.
WFC WFCNP AMD LB SCHW MSFT
By most measures, Bank of America (NYSE:BAC) shares should be moving higher right now. BAC stock’s third-quarter earnings as well as revenue were both better than expected, and both up on a year-over-year basis.
WFC WFCNP C BAC JPM
SAN FRANCISCO (AP) — San Francisco has come to be known around the world as a place for aggressive panhandling, open-air drug use and sprawling tent camps, the dirt and despair all the more remarkable for the city's immense wealth.
WFC WFCNP MCK AAPL GPS
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Amazon (AMZN), Broadcom (AVGO) and Lockheed Martin (LMT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP LMT BCE AVGO WFC STT UPS
Filed Pursuant to Rule 424(b)(2) Registration No. 333-221324
On today’s episode of Free Lunch, Ryan McQueeney recaps morning news from Wall Street, including tensions between the U.S. and Saudi Arabia, big bank earnings, and historic data from Activision Blizzard. The host also covers the bankruptcy of Sears, September’s retail sales results, and holiday shopping expectations.
WFC WFCNP BAC C ATVI BAC SHLD SHLDW
Bank of America Corp reported a better-than-expected rise in quarterly profit on Monday as the second-largest U.S. lender reined in costs, while higher interest rates and loan growth helped offset lower bond trading revenue.
WFCNP WFC C CGBBW
(Reuters) - Bank of America Corp’s (BAC.N) loan growth lagged rivals and fees from advising on deals and underwriting bonds fell in the third quarter, sending its share price almost 3 percent lower, even as profit beat expectations.
WFCNP WFC C CGBBW
Despite dismal investment banking and trading performance, loan growth, higher interest rates and tax cuts drove Bank of America’s (BAC - Free Report) third-quarter 2018 earnings of 66 cents per share, which handily outpaced the Zacks Consensus Estimate of 62 cents. Also, the figure was 44% higher than the prior-year quarter. Shares of BofA rose nearly 1% in the pre-market trading, indicating that investors have taken the results in their stride.
WFC WFCNP BAC C BAC GPN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET